BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 29078260)

  • 1. Dihydromyricetin prevents monocrotaline-induced pulmonary arterial hypertension in rats.
    Li Q; Wang J; Zhu X; Zeng Z; Wu X; Xu Y; Xie J; Yu J
    Biomed Pharmacother; 2017 Dec; 96():825-833. PubMed ID: 29078260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of AMPK prevents monocrotaline-induced pulmonary arterial hypertension by suppression of NF-κB-mediated autophagy activation.
    Zhai C; Shi W; Feng W; Zhu Y; Wang J; Li S; Yan X; Wang Q; Zhang Q; Chai L; Li C; Liu P; Li M
    Life Sci; 2018 Sep; 208():87-95. PubMed ID: 30009823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Shp2 ameliorates monocrotaline-induced pulmonary arterial hypertension in rats.
    Cheng Y; Yu M; Xu J; He M; Wang H; Kong H; Xie W
    BMC Pulm Med; 2018 Aug; 18(1):130. PubMed ID: 30086741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tetrandrine prevents monocrotaline-induced pulmonary arterial hypertension in rats through regulation of the protein expression of inducible nitric oxide synthase and cyclic guanosine monophosphate-dependent protein kinase type 1.
    Wang X; Yang Y; Yang D; Tong G; Lv S; Lin X; Chen C; Dong W
    J Vasc Surg; 2016 Nov; 64(5):1468-1477. PubMed ID: 26527422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Let-7a-transfected mesenchymal stem cells ameliorate monocrotaline-induced pulmonary hypertension by suppressing pulmonary artery smooth muscle cell growth through STAT3-BMPR2 signaling.
    Cheng G; Wang X; Li Y; He L
    Stem Cell Res Ther; 2017 Feb; 8(1):34. PubMed ID: 28187784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aspirin attenuates monocrotaline-induced pulmonary arterial hypertension in rats by suppressing the ERK/MAPK pathway.
    Gao H; Cheng Y; Zong L; Huang L; Qiao C; Li W; Gong B; Hu J; Liu H; Wang X; Zhao C
    Clin Exp Hypertens; 2017; 39(1):34-41. PubMed ID: 28055284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resveratrol reverses monocrotaline-induced pulmonary vascular and cardiac dysfunction: a potential role for atrogin-1 in smooth muscle.
    Paffett ML; Lucas SN; Campen MJ
    Vascul Pharmacol; 2012; 56(1-2):64-73. PubMed ID: 22146233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats.
    Yang PS; Kim DH; Lee YJ; Lee SE; Kang WJ; Chang HJ; Shin JS
    Respir Res; 2014 Nov; 15():148. PubMed ID: 25420924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension.
    Behringer A; Trappiel M; Berghausen EM; Ten Freyhaus H; Wellnhofer E; Odenthal M; Blaschke F; Er F; Gassanov N; Rosenkranz S; Baldus S; Kappert K; Caglayan E
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Apr; 389(4):369-79. PubMed ID: 26742933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baicalein attenuates monocrotaline-induced pulmonary arterial hypertension by inhibiting vascular remodeling in rats.
    Shi R; Wei Z; Zhu D; Fu N; Wang C; Yin S; Liang Y; Xing J; Wang X; Wang Y
    Pulm Pharmacol Ther; 2018 Feb; 48():124-135. PubMed ID: 29133079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eicosapentaenoic acid ameliorates pulmonary hypertension via inhibition of tyrosine kinase Fyn.
    Kurahara LH; Hiraishi K; Yamamura A; Zhang Y; Abe K; Yahiro E; Aoki M; Koga K; Yokomise H; Go T; Ishikawa K; Bo Z; Kishi H; Kobayashi S; Aoki-Shoi N; Toru S; Inoue R; Hirano K
    J Mol Cell Cardiol; 2020 Nov; 148():50-62. PubMed ID: 32889002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of cordycepin in the treatment of pulmonary arterial hypertension in rats based on metabonomics and transcriptomics.
    Lin J; Chen R; Liao H; Zhang Y; Zheng Z; Hong C
    Sci Rep; 2024 May; 14(1):12431. PubMed ID: 38816406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thymoquinone attenuates monocrotaline-induced pulmonary artery hypertension via inhibiting pulmonary arterial remodeling in rats.
    Zhu N; Zhao X; Xiang Y; Ye S; Huang J; Hu W; Lv L; Zeng C
    Int J Cardiol; 2016 Oct; 221():587-96. PubMed ID: 27420584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic effects of baicalin on monocrotaline-induced pulmonary arterial hypertension by inhibiting inflammatory response.
    Luan Y; Chao S; Ju ZY; Wang J; Xue X; Qi TG; Cheng GH; Kong F
    Int Immunopharmacol; 2015 May; 26(1):188-93. PubMed ID: 25601497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydrogen ameliorates pulmonary hypertension in rats by anti-inflammatory and antioxidant effects.
    Kishimoto Y; Kato T; Ito M; Azuma Y; Fukasawa Y; Ohno K; Kojima S
    J Thorac Cardiovasc Surg; 2015 Sep; 150(3):645-54.e3. PubMed ID: 26095621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-Aminosalicylic Acid Attenuates Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats by Increasing the Expression of Nur77.
    Sun LY; Cai ZY; Pu J; Li J; Shen JY; Yang CD; He B
    Inflammation; 2017 Jun; 40(3):806-817. PubMed ID: 28213866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical role for the advanced glycation end-products receptor in pulmonary arterial hypertension etiology.
    Meloche J; Courchesne A; Barrier M; Carter S; Bisserier M; Paulin R; Lauzon-Joset JF; Breuils-Bonnet S; Tremblay É; Biardel S; Racine C; Courture C; Bonnet P; Majka SM; Deshaies Y; Picard F; Provencher S; Bonnet S
    J Am Heart Assoc; 2013 Jan; 2(1):e005157. PubMed ID: 23525442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perillyl alcohol suppresses monocrotaline-induced pulmonary arterial hypertension in rats via anti-remodeling, anti-oxidant, and anti-inflammatory effects.
    Beik A; Najafipour H; Joukar S; Rajabi S; Iranpour M; Kordestani Z
    Clin Exp Hypertens; 2021 Apr; 43(3):270-280. PubMed ID: 33322932
    [No Abstract]   [Full Text] [Related]  

  • 19. A urotensin II receptor antagonist, KR36676, decreases vascular remodeling and inflammation in experimental pulmonary hypertension.
    Lee JH; Park BK; Oh KS; Yi KY; Lim CJ; Seo HW; Lee BH
    Int Immunopharmacol; 2016 Nov; 40():196-202. PubMed ID: 27611861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ranolazine prevents INaL enhancement and blunts myocardial remodelling in a model of pulmonary hypertension.
    Rocchetti M; Sala L; Rizzetto R; Staszewsky LI; Alemanni M; Zambelli V; Russo I; Barile L; Cornaghi L; Altomare C; Ronchi C; Mostacciuolo G; Lucchetti J; Gobbi M; Latini R; Zaza A
    Cardiovasc Res; 2014 Oct; 104(1):37-48. PubMed ID: 25139747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.